Home » News » Drug Sponsors » SillaJen completes Jennerex acquisition

SillaJen completes Jennerex acquisition

Monday, March 17, 2014

SillaJen, a privately held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, has completed the acquisition of San Francisco-based Jennerex. Privately held Jennerex is a clinical-stage, biotherapeutics company developing best-in-class targeted oncolytic immunotherapies.

SillaJen will continue the development of late-stage product Pexa-Vec (JX-594), as well as products from both companies’ pipelines. Jennerex now is a wholly-owned subsidiary of SillaJen.

David Kirn, founder of Jennerex and chairman of the SillaJen board of directors, said, “SillaJen’s acquisition of its long-standing R&D partner positions it as the world leader in oncolytic immunotherapy. Positive Pexa-Vec clinical data have recently been published in leading peer-reviewed journals, including Nature and Nature Medicine. The potential of this emerging multi-mechanistic therapeutic class also has been validated by the demonstration of a survival benefit in front-line advanced cancer patients with both Pexavec and Amgen’s T-Vec in randomized phase II and III trials, respectively. We look forward to working with our global partners to bring Pexa-Vec into a phase III pivotal trial for front-line treatment of patients with advanced liver cancer. Pexa-Vec also has demonstrated objective and durable tumor responses in other common cancer types, and these will be the focus of upcoming clinical trials. These trials will study Pexa-Vec as both a single agent and in combination with checkpoint inhibitor therapies.”

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!